Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277690 | 0.91 | HSD11B1 (0.57) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL4760623 | 0.91 | HSD11B1 (0.57) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL4760751 | 0.88 | CTSK (0.50) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL17323937 | 0.88 | EPHX2 (0.57) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL13459453 | 0.87 | CTSK (0.51) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL907562 | 0.87 | CTSK (0.51) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL14417805 | 0.87 | CTSK (0.51) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL12661411 | 0.87 | CTSK (0.51) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL14417798 | 0.86 | CTSK (0.48) | CTSKHSD11B1EPHX1CYP2C9CA1 | |
| SCHEMBL4760808 | 0.85 | CTSK (0.50) | CTSKHSD11B1EPHX1CYP2C9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8039470-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039470-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261665-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2008033562-A2 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885HSD11B1 2215/4885EPHX1 1568/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885HSD11B1 2215/4885EPHX1 1568/4885 |
| US-20100261665-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885HSD11B1 2215/4885EPHX1 1568/4885 |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | CTSK 571/4885HSD11B1 2215/4885EPHX1 1568/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | CTSK 2660/4885HSD11B1 50/4885EPHX1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.